HomeAI · summaries
Storia in 5 fonti
Incyte Bets $1.25 Billion On Rare Bleeding Disorder Drug With Blockbuster Potential - Incyte (NASDAQ:INCY
Incyte to acquire Vega Therapeutics for $1.25 billion upfront, adding a rare bleeding disorder candidate with blockbuster potential in 2030s.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Incyte to buy blood disorder drug in possibly $2B deal
Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.
- ·
morningstar.com
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding…
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
